Future trials should prospectively measure CRP, ESR, and other cytokine biomarkers in parallel to define their relative thresholds and clarify their role alongside clinical scores like IHS4 and HiSCR in guiding TNF-alpha inhibitor therapy in HS. Here, TNF is linked to histiocytic sarcoma.